426268-09-9 Usage
General Description
Benzo[c][1,2,5]oxadiazole-5-boronic acid is a chemical compound with the molecular formula C8H6BNO3. It is a boronic acid derivative with a unique heterocyclic structure that contains a benzene and oxadiazole ring fused together. Benzo[c][1,2,5]oxadiazole-5-boronic acid has potential applications in the field of organic synthesis, medicinal chemistry, and materials science. Boronic acids are known for their ability to react with various nucleophiles, making them useful reagents in the formation of carbon-carbon and carbon-heteroatom bonds. Additionally, the oxadiazole ring in this compound is a versatile pharmacophore with bioactive properties, giving it potential as a building block for drug discovery and development. Further research and exploration of the chemical properties and applications of Benzo[c][1,2,5]oxadiazole-5-boronic acid are ongoing, with the potential for it to have important implications in various scientific fields.
Check Digit Verification of cas no
The CAS Registry Mumber 426268-09-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,2,6,2,6 and 8 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 426268-09:
(8*4)+(7*2)+(6*6)+(5*2)+(4*6)+(3*8)+(2*0)+(1*9)=149
149 % 10 = 9
So 426268-09-9 is a valid CAS Registry Number.
426268-09-9Relevant articles and documents
Large-scale Negishi coupling as applied to the synthesis of PDE472, an inhibitor of phosphodiesterase type 4D
Manley, Paul W.,Acemoglu, Murat,Marterer, Wolfgang,Pachinger, Werner
, p. 436 - 445 (2013/09/06)
5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole (PDE472) is a selective inhibitor of the phosphodiesterase PDE4D isoenzyme, which is a recognised drug target for the treatment of asthma. Different synthetic routes to PDE472 were investigated, and the research synthesis was optimised to prepare a phase I batch on pilot-plant scale with the focus on the elimination or minimization of inherent process risks. An important refinement of the key Negishi aryl-aryl coupling involved preforming the arylpalladium complex, which was then added to the arylzinc intermediate. Residual palladium was removed from PDE472 via crystallization of the hemi-maleate salt, which afforded drug-substance containing 2 ppm Pd.
